RECEIVED

MAR 1 2 2003

TECH CENTER 1600/2900



Case SO-291 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Vianello, et. al.)	GROUP ART UNIT: 1624
SERIAL NO. 09/924,709)	EXAMINER: R. Raymond
FILED: August 8, 2001)	DATE: March 6, 2003

TITLE: Novel Substituted Benzoxazines as Integrin Antagonists

Assistant Commissioner of Patents Washington, D.C. 20231

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

Please charge the fee of \$180.00 as required by 37 C.F.R. § 1.17(p) to Deposit Account No. 19-1025. No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

03/12/2003 NOSCHER 00000018 891025 09924709

100.00 CM

02 FC:13C3

Respectfully submitted,

Rachel A. Polster, Agent Registration No. 47,004 (314) 274-7354 (St. Louis)

Pharmacia Corporation Global Patent Department P. O. Box 1027 St. Louis, MO 63006